Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Adial Pharmaceuticals, Inc. (ADIL) had Return on Tangible Equity of -104.96% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-2.23M |
|
-- |
|
-- |
|
$2.27M |
|
$-2.27M |
|
$0.04M |
|
$-2.23M |
|
$-2.23M |
|
$-2.23M |
|
$-2.23M |
|
$-2.23M |
|
$-2.23M |
|
$-2.27M |
|
$-2.27M |
|
6.54M |
|
6.54M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$2.63M |
|
-- |
|
$0.82M |
|
$3.45M |
|
$1.32M |
|
-- |
|
-- |
|
$1.32M |
|
$2.13M |
|
$2.12M |
|
$2.13M |
|
6.65M |
|
| Cash Flow Statement Financials | |
$-1.59M |
|
$0.15M |
|
$0.05M |
|
$3.75M |
|
$2.37M |
|
$-1.38M |
|
$0.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.99 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-104.80% |
|
|
Return on Tangible Equity |
-104.96% |
-64.58% |
|
-104.80% |
|
$0.32 |
|
$-0.24 |
|
$-0.24 |
|